CXCR2 signaling regulates KRAS(G12D)-induced autocrine growth of pancreatic cancer

Oncotarget

Volumn 7, Issue 6, 2016, Pages 7280-7296

  Purohit, Abhilasha ^a   Varney, Michelle ^a   Rachagani, Satyanarayana ^a   Ouellette, Michel M ^a   Batra, Surinder K ^a   Singh, Rakesh K ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Autocrine growth; CXCR2; ERK; KRAS(G12D); PDAC

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; KRAS PROTEIN, HUMAN; PROTEIN P21;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; CELL MOTION; DRUG SCREENING; GENETICS; METABOLISM; MUTATION; NUDE MOUSE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; AUTOCRINE COMMUNICATION; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, NUDE; MUTATION; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTORS, INTERLEUKIN-8B; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84980695639     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6906     Document Type: Article

References (44)

1. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015; 65:5-29.
2. Vincent A, Herman J, Schulick R, Hruban RH and Goggins M. Pancreatic cancer. Lancet. 2011; 378:607-620.
3. Bryant KL, Mancias JD, Kimmelman AC and Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends in biochemical sciences. 2014; 39:91-100.
4. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA and Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer research. 2007; 67:9518-9527.
5. Burkholder B, Huang R-Y, Burgess R, Luo S, Jones VS, Zhang W, Lv Z-Q, Gao C-Y, Wang B-L and Zhang Y-M. Tumor-induced perturbations of cytokines and immune cell networks. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2014; 1845:182-201.
6. Crusz SM and Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015; 12:584-596.
7. Suzuki A, Leland P, Joshi BH and Puri RK. Targeting of IL-4 and IL-13 receptors for cancer therapy. Cytokine. 2015; 75:79-88.
8. Zlotnik A and Yoshie O. The chemokine superfamily revisited. Immunity. 2012; 36:705-716.
9. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews Cancer. 2004; 4:11-22.
10. Ancrile BB, O'Hayer KM and Counter CM. Oncogenic Ras-Induced Expression of Cytokines in Cancer. Molecular interventions. 2008; 8:22.
11. Chapman R, Phillips J, Hipkin R, Curran A, Lundell D and Fine J. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacology & therapeutics. 2009; 121:55-68.
12. Katoh H, Wang D, Daikoku T, Sun H, Dey SK and DuBois RN. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer cell. 2013; 24:631-644.
13. Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J and Lin S-H. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clinical Cancer Research. 2010; 16:3875-3886.
14. Kuwada Y, Sasaki T, Morinaka K, Kitadai Y, Mukaida N and Chayama K. Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. International journal of oncology. 2003; 22:765-771.
15. Oliveira Frick V, Rubie C, Wagner M, Graeber S, Grimm H, Kopp B, Rau BM and Schilling MK. Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases. Pancreatology. 2008; 8:488-497.
16. Li A, King J, Moro A, Sugi MD, Dawson DW, Kaplan J, Li G, Lu X, Strieter RM and Burdick M. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. The American journal of pathology. 2011; 178:1340-1349.
17. Matsuo Y, Campbell PM, Brekken RA, Sung B, Ouellette MM, Fleming JB, Aggarwal BB, Der CJ and Guha S. K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. Molecular Cancer Research. 2009; 7:799-808.
18. Takamori H, Oades ZG, Hoch OC, Burger M and Schraufstatter IU. Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1. Pancreas. 2000; 21:52-56.
19. Wang S, Wu Y, Hou Y, Guan X, Castelvetere MP, Oblak JJ, Banerjee S, Filtz TM, Sarkar FH and Chen X. CXCR2 macromolecular complex in pancreatic cancer: a potential therapeutic target in tumor growth. Translational oncology. 2013; 6:216-225.
20. Miyamoto M, Shimizu Y, Okada K, Kashii Y, Higuchi K and Watanabe A. Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells. Cancer Immunology, Immunotherapy. 1998; 47:47-57.
21. Thompson N and Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Current opinion in pharmacology. 2005; 5:350-356.
22. Della Rocca GJ, van Biesen T, Daaka Y, Luttrell DK, Luttrell LM and Lefkowitz RJ. Ras-dependent mitogen-activated protein kinase activation by G protein-coupled receptors Convergence of Gi-and Gq-mediated pathways on calcium/calmodulin, Pyk2, and Src kinase. Journal of Biological Chemistry. 1997; 272:19125-19132.
23. Li M, Zhang Y, Feurino LW, Wang H, Fisher WE, Brunicardi FC, Chen C and Yao Q. Interleukin8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer. Cancer science. 2008; 99:733-737.
24. Wang D, Yang W, Du J, Devalaraja MN, Liang P, Matsumoto K, Tsubakimoto K, Endo T and Richmond A. MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression. Oncogene. 2000; 19:4647.
25. Cheng W-L, Wang C-S, Huang Y-H, Tsai M-M, Liang Y and Lin K-H. Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Annals of oncology. 2011:mdq739.
26. Hingorani SR, Petricoin III EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD and Hitt BA. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer cell. 2003; 4:437-450.
27. Torres MP, Rachagani S, Souchek JJ, Mallya K, Johansson SL and Batra SK. Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy. PloS one. 2013; 8:e80580.
28. Singh S, Sadanandam A, Nannuru KC, Varney ML, Mayer-Ezell R, Bond R and Singh RK. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clinical Cancer Research. 2009; 15:2380-2386.
29. Downward J. Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer. 2003; 3:11-22.
30. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C and Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nature Reviews Cancer. 2013; 13:759-771.
31. Collins MA, Bednar F, Zhang Y, Brisset J-C, Galbán S, Galbán CJ, Rakshit S, Flannagan KS, Adsay NV and di Magliano MP. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. The Journal of clinical investigation. 2012; 122:639.
32. Ijichi H, Chytil A, Gorska AE, Aakre ME, Bierie B, Tada M, Mohri D, Miyabayashi K, Asaoka Y and Maeda S. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. The Journal of clinical investigation. 2011; 121:4106.
33. O'Hayer KM, Brady DC and Counter CM. ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis. Carcinogenesis. 2009; 30:1841-1847.
34. Sparmann A and Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer cell. 2004; 6:447-458.
35. Yang G, Rosen DG, Zhang Z, Bast RC, Mills GB, Colacino JA, Mercado-Uribe I and Liu J. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proceedings of the National Academy of Sciences. 2006; 103:16472-16477.
36. Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, Tang H, Burdick MD, Sato M and Minna JD. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer research. 2006; 66:4198-4207.
37. Kamohara H, Takahashi M, Ishiko T, Ogawa M and Baba H. Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-α and leukemia inhibitory factor in pancreatic carcinoma cells: Impact of CXCL-8 as an autocrine growth factor. International journal of oncology. 2007; 31:627-632.
38. Garassino M, Marabese M, Rusconi P, Rulli E, Martelli O, Farina G, Scanni A and Broggini M. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Annals of oncology. 2011; 22:235-237.
39. Varney ML, Singh S, Li A, Mayer-Ezell R, Bond R and Singh RK. Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer letters. 2011; 300:180-188.
40. Ning Y, Labonte MJ, Zhang W, Bohanes PO, Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO and Venkata KCN. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Molecular cancer therapeutics. 2012; 11:1353-1364.
41. Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni P, Tsai M, Sadeh J and Magnussen H. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. European Respiratory Journal. 2010; 35:564-570.
42. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V and Der CJ. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer research. 2007; 67:2098-2106.
43. Rachagani S, Senapati S, Chakraborty S, Ponnusamy MP, Kumar S, Smith L, Jain M and Batra SK. Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. British journal of cancer. 2011; 104:1038-1048.
44. Li A, Varney ML and Singh RK. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clinical Cancer Research. 2001; 7:3298-3304.